RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
REPLIGEN CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $784.79M | $763.03M | $737.96M | $707.63M | $673.69M | $650.17M | $634.18M | $633.13M | $619.46M | $619.78M | $631.98M | $652.15M | 100.0% | +16.5% |
| Royalty and Other Revenue | $311.00K | $305.00K | $296.00K | $264.00K | $262.00K | $260.00K | $261.00K | $380.00K | $379.00K | $380.00K | $383.00K | $358.00K | 0.0% | +18.7% |
By region
From the segment and revenue-disaggregation notes of Repligen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.